Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine on Inflammatory Response in Lung Resection
NCT04007341Completed
- Sponsor
- Seoul St. Mary's Hospital
- Start
- Jul 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexmedetomidine in lung cancer (2 arms), sponsored by Seoul St. Mary's Hospital. Primary endpoint: Interleukin-6. Started Jul 2018; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT04007341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04007341.